Several methods offer the sensitivity to perform cell-free DNA (cfDNA) diagnostics for a broad range of indications, such as cancer, autoimmune diseases and cardiovascular diseases in professional molecular laboratories. However, the bottleneck for the blood-based liquid biopsies diagnostic approaches is the variation in the sample quality and logistics, which reduce the effective utilization of the diagnostics. BiopSense project was launched for the development of a new point-of care platform, based on the semicondúctor technology. To enable this, a new approach for sample prep was generated and patenting started.
During the project, a new start-up, BiopSense Ltd, was launched, and the IPR right were transferred to this company by the end off the project. This company provides diagnostic services and develops novel technologies for cfDNA sample processing and logistics. The new cfDNA extraction Cartridge may advance sample stability, automate purification, and enable high transportability of the samples all over the world. The Cartridge offers added value through increased cfDNA quality and spared labor costs. In addition, the product also matches the future point-of-care market trends by providing point-of-care customer experience by exceptional transportability of the cfDNA samples, enabling strategic changes in the current business models of diagnostics companies. BiopSense company also provides liquid biopsy and COVID-19 diagnostic services for the Finnish health care sector. The company has employed over ten newly maturated molecular biologists for corona works, and aims to provide an inspiring environment for young researchers for developing focused R&D project in the city of Jyväskylä, Finland.
